- Home
- TSHA vs NPCE Comparison
TSHA vs NPCE Comparison
Compare TSHA & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- NPCE
- Stock Information
- Founded
- TSHA 2019
- NPCE 1997
- Country
- TSHA United States
- NPCE United States
- Employees
- TSHA N/A
- NPCE N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- TSHA Health Care
- NPCE Health Care
- Exchange
- TSHA Nasdaq
- NPCE Nasdaq
- Market Cap
- TSHA 397.8M
- NPCE 358.3M
- IPO Year
- TSHA 2020
- NPCE 2021
- Fundamental
- Price
- TSHA $2.71
- NPCE $13.22
- Analyst Decision
- TSHA Strong Buy
- NPCE Buy
- Analyst Count
- TSHA 7
- NPCE 7
- Target Price
- TSHA $7.00
- NPCE $15.14
- AVG Volume (30 Days)
- TSHA 5.2M
- NPCE 482.1K
- Earning Date
- TSHA 05-15-2025
- NPCE 05-13-2025
- Dividend Yield
- TSHA N/A
- NPCE N/A
- EPS Growth
- TSHA N/A
- NPCE N/A
- EPS
- TSHA N/A
- NPCE N/A
- Revenue
- TSHA $7,224,000.00
- NPCE $84,306,000.00
- Revenue This Year
- TSHA N/A
- NPCE $20.74
- Revenue Next Year
- TSHA N/A
- NPCE $12.47
- P/E Ratio
- TSHA N/A
- NPCE N/A
- Revenue Growth
- TSHA N/A
- NPCE 22.05
- 52 Week Low
- TSHA $1.05
- NPCE $5.45
- 52 Week High
- TSHA $4.32
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- TSHA 60.38
- NPCE 45.90
- Support Level
- TSHA $2.44
- NPCE $10.61
- Resistance Level
- TSHA $2.95
- NPCE $18.98
- Average True Range (ATR)
- TSHA 0.25
- NPCE 1.63
- MACD
- TSHA -0.02
- NPCE -0.45
- Stochastic Oscillator
- TSHA 51.60
- NPCE 31.20
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.